CCT129202 manufacturers
- CCT129202
-
- $39.00 / 1mg
-
2025-04-29
- CAS:942947-93-5
- Min. Order:
- Purity: 98.14%
- Supply Ability: 10g
- CCT129202
-
- $1.00 / 1g
-
2020-01-09
- CAS:942947-93-5
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 200kg
|
| | CCT129202 Basic information |
| Product Name: | CCT129202 | | Synonyms: | CCT129202;2-[4-[6-Chloro-2-(4-dimethylaminophenyl)-3H-imidazo[4,5-b]pyridin-7-yl]piperazin-1-yl]-N-(thiazol-2-yl)acetamide;2-(4-(6-Chloro-2-(4-(dimethylamino)phenyl)-1H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)-N-(th;CCT129202
(CCT-129202;CS-407;CCT129202 USP/EP/BP;1-Piperazineacetamide, 4-[6-chloro-2-[4-(dimethylamino)phenyl]-3H-imidazo[4,5-b]pyridin-7-yl]-N-2-thiazolyl- | | CAS: | 942947-93-5 | | MF: | C23H25ClN8OS | | MW: | 497.02 | | EINECS: | | | Product Categories: | Inhibitor;Inhibitors | | Mol File: | 942947-93-5.mol |  |
| | CCT129202 Chemical Properties |
| density | 1.427 | | storage temp. | Store at -20°C | | solubility | DMSO : 1 mg/mL (2.01 mM; Need ultrasonic) | | form | Powder | | pka | 9.26±0.50(Predicted) | | color | Light yellow to yellow |
| | CCT129202 Usage And Synthesis |
| Uses | CCT129202 is an aurora kinase inhibitor with IC50s of 42, 198, and 227 nM for aurora A, B and C, respectively. | | Biological Activity | CCT129202 is an ATP-competitive pan-Aurora inhibitor with IC50s of 0.042 μM, 0.198 μM and 0.227 μM for Aurora A, Aurora B and Aurora C, respectively, and has a weaker effect on FGFR3, GSK3β, PDGFRβ, etc. | | in vivo | CCT129202 at a dose of 100 mg/kg subcutaneously injected HCT116 colon xenografts in athymic mice, after 30 minutes, caused a ~50% decrease in histone H3 phosphorylation, and after 9 days of treatment, significantly inhibited tumor growth, compared with the control group , inhibited by 57.7%. | | target | Aurora A | | IC 50 | Aurora A: 42 nM (IC50); Aurora B: 198 nM (IC50); Aurora C: 227 nM (IC50) | | References | [1] Chan F, et al. Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3147-57. DOI:10.1158/1535-7163.MCT-07-2156 |
| | CCT129202 Preparation Products And Raw materials |
|